Drug shortage
Amphetamine Aspartate Monohydrate · Oryza Pharmaceuticals Inc.
FDA drug shortage · Current · updated Sep 16, 2026
Key facts
| Generic name | Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet |
|---|---|
| Company | Oryza Pharmaceuticals Inc. |
| Presentation | Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01) |
| Dosage form | Tablet |
| Status | Current |
| Reason for shortage | Shortage of an active ingredient |
| Therapeutic category | Psychiatry |
| Package NDCs | 72516-016-01 |
| First posted | Oct 12, 2022 |
| Last updated | Sep 16, 2026 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: